William Blair Initiates Coverage on Vor Biopharma (NASDAQ:VOR)

Equities research analysts at William Blair assumed coverage on shares of Vor Biopharma (NASDAQ:VOR) in a report released on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating on the stock.

Several other brokerages have also recently issued reports on VOR. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Citigroup upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, October 15th. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Finally, Wedbush increased their price target on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Vor Biopharma Trading Up 5.5%

Vor Biopharma stock opened at $19.03 on Wednesday. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $30.38. The company’s 50 day moving average is $21.38 and its two-hundred day moving average is $18.41.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, equities analysts forecast that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at $2,298,000. Bank of America Corp DE grew its stake in shares of Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after purchasing an additional 112,496 shares in the last quarter. Braidwell LP grew its stake in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after purchasing an additional 106,330 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma during the second quarter worth $1,799,000. Finally, Simplify Asset Management Inc. purchased a new position in Vor Biopharma in the first quarter valued at $955,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.